Neurosetta has developed RosetteArray technology, a high-throughput human brain and spinal cord modeling platform that is transforming developmental neurotoxicity (DNT) testing and drug development for neurodevelopmental disorders. It is impossible to conduct chemical safety and drug screening on such embryonic tissues in human embryos. Yet, science is informing us that neurodevelopmental disorders have disease origins within this window of human development. Neurosetta’s human stem cell-derived, 3-D, brain and spinal RosetteArrays now make modeling of this critical developmental stage possible in an off-the-shelf, scalable, screening and analysis platform. Thus, the company’s patent-pending RosetteArray platform enables rapid, cost-efficient human DNT testing and disease modeling for drug discovery.
Presented at WARF Innovation Day at Summerfest Tech on June 29, 2022, by Randolph Ashton, Associate Professor of Biomedical Engineering at UW-Madison and Co-Founder/CEO of Neurosetta LLC.